NCT02682862View on ClinicalTrials.gov

Ultra-long Acting Bronchodilator Therapy in Smoking Asthmatics

PHASE4CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

July 11, 2016

Primary Completion Date

May 22, 2019

Study Completion Date

May 22, 2019

Conditions
Asthma
Interventions
DRUG

olodaterol hydrochloride 2.5mcg, tiotropium bromide 2.5mcg

Inhaler: 2.5 microgram tiotropium (as bromide monohydrate) and 2.5 microgram olodaterol (as hydrochloride) per puff. 2 puffs once daily

DRUG

olodaterol 2.5 mcg

Inhaler: 2.5 microgram Olodaterol (as hydrochloride) per puff. 2 puffs once daily

Trial Locations (1)

DD1 9SY

Scottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee

All Listed Sponsors
lead

University of Dundee

OTHER

NCT02682862 - Ultra-long Acting Bronchodilator Therapy in Smoking Asthmatics | Biotech Hunter | Biotech Hunter